• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发展中国家多标准决策分析框架实施指南。

Guidance toward the implementation of multicriteria decision analysis framework in developing countries.

作者信息

Inotai András, Nguyen Huong Thanh, Hidayat Budi, Nurgozhin Talgat, Kiet Pham Huy Tuan, Campbell Jonathan D, Németh Bertalan, Maniadakis Nikos, Brixner Diana, Wijaya Kalman, Kaló Zoltán

机构信息

a Syreon Research Institute , Budapest , Hungary.

b Department of Health Policy and Health Economics , Eötvös Loránd University (ELTE) , Budapest , Hungary.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):585-592. doi: 10.1080/14737167.2018.1508345. Epub 2018 Aug 24.

DOI:10.1080/14737167.2018.1508345
PMID:30092151
Abstract

Multiple Criteria Decision Analysis (MCDA) is increasingly used in health care mainly because it moves decision-making from ad hoc to an evidence-based and comprehensive process. Developing countries with more restricted financial and human research capacities, however, should consider their own methods of MCDA development and implementation. Areas covered: An MCDA framework to improve procurement decisions of off-patent pharmaceuticals was developed for developing countries and adapted to Indonesia, Kazakhstan and Vietnam during three policy workshops. Based on the experience of these workshops and one joint workshop with international experts and decision makers from multiple developing countries, general recommendations were formulated on how to implement MCDA specifically in developing countries. We provide 17 practical MCDA implementation recommendations in four major areas, including (1) MCDA objectives; (2) technical considerations of MCDA tool; (3) development and customization of MCDA tool and (4) policy implementation of MCDA in decision-making. Expert commentary: These practical MCDA recommendations for developing countries contribute to feasible, transparent, stepwise, iterative and standardized decision-making in health care.

摘要

多标准决策分析(MCDA)在医疗保健领域的应用日益广泛,主要是因为它将决策过程从临时决策转变为基于证据的全面过程。然而,财政和人力研究能力较为有限的发展中国家应考虑适合自身的MCDA开发与实施方法。涵盖领域:为发展中国家开发了一个用于改进非专利药品采购决策的MCDA框架,并在三次政策研讨会上对印度尼西亚、哈萨克斯坦和越南进行了调整。基于这些研讨会以及一次与国际专家和多个发展中国家决策者共同举办的联合研讨会的经验,就如何在发展中国家具体实施MCDA提出了一般性建议。我们在四个主要领域提供了17条MCDA实施实用建议,包括:(1)MCDA目标;(2)MCDA工具的技术考量;(3)MCDA工具的开发与定制;(4)MCDA在决策中的政策实施。专家评论:这些针对发展中国家的MCDA实用建议有助于在医疗保健领域实现可行、透明、逐步、迭代和标准化的决策。

相似文献

1
Guidance toward the implementation of multicriteria decision analysis framework in developing countries.发展中国家多标准决策分析框架实施指南。
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):585-592. doi: 10.1080/14737167.2018.1508345. Epub 2018 Aug 24.
2
Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.非专利药品多标准决策分析(MCDA)框架的开发——以改善印度尼西亚的招标决策为例
BMC Health Serv Res. 2018 Dec 29;18(1):1003. doi: 10.1186/s12913-018-3805-3.
3
Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.应用多标准决策分析(MCDA)简单评分法作为一种基于证据的卫生技术评估方法,用于评估新兴市场中的非专利药品(OPPs)。
Value Health Reg Issues. 2017 Sep;13:1-6. doi: 10.1016/j.vhri.2017.02.001. Epub 2017 May 11.
4
An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.新兴市场卫生技术评估中专利过期药品审查的证据框架
Value Health Reg Issues. 2018 Sep;16:9-13. doi: 10.1016/j.vhri.2018.01.003. Epub 2018 Mar 30.
5
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。
Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.
6
How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review.多标准决策分析如何支持药品的价值评估?——系统文献综述的结果
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):379-391. doi: 10.1080/14737167.2018.1467759. Epub 2018 Apr 29.
7
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验
Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.
8
Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.在一个假设情境中,基于多标准决策分析的药物效益-风险概况排名与直观排名之间的差异。
J Clin Pharm Ther. 2017 Feb;42(1):80-86. doi: 10.1111/jcpt.12486. Epub 2016 Dec 2.
9
Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE.关于在阿联酋支持通用药品基于价值采购的试点多标准决策分析(MCDA)工具的建议。
Front Pharmacol. 2021 Jun 8;12:680737. doi: 10.3389/fphar.2021.680737. eCollection 2021.
10
Knowledge Translation in Practice: Exploring the Potential Use of MCDA in Central America and the Caribbean.实践中的知识转化:探索多标准决策分析在中美洲和加勒比地区的潜在应用
Value Health Reg Issues. 2018 Dec;17:148-149. doi: 10.1016/j.vhri.2018.07.003. Epub 2018 Sep 2.

引用本文的文献

1
Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.阿联酋罕见病药物多标准决策分析工具的开发。
Cureus. 2024 Feb 29;16(2):e55215. doi: 10.7759/cureus.55215. eCollection 2024 Feb.
2
A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply.一种针对药品多赢家招标的概念,兼顾有效价格、长期竞争和供应可持续性。
Front Med (Lausanne). 2023 Oct 30;10:1282698. doi: 10.3389/fmed.2023.1282698. eCollection 2023.
3
Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods.
罕见病患者体验价值要素框架:一项展示定性和定量方法相结合适用性的案例研究
Pharmacoecon Open. 2023 Mar;7(2):217-228. doi: 10.1007/s41669-022-00376-w. Epub 2022 Nov 1.
4
A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt.埃及用于采购非专利肿瘤药物的多标准决策分析(MCDA)工具。
J Pharm Policy Pract. 2022 Mar 1;15(1):10. doi: 10.1186/s40545-022-00414-2.
5
Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings.增值药物核心评估框架的制定:方法与结果报告1
Cost Eff Resour Alloc. 2021 Aug 31;19(1):57. doi: 10.1186/s12962-021-00311-6.
6
The CAPACITI Decision-Support Tool for National Immunization Programs.国家免疫规划决策支持工具 CAPACITI。
Value Health. 2021 Aug;24(8):1150-1157. doi: 10.1016/j.jval.2021.04.1273. Epub 2021 Jun 18.
7
Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives.增值药物核心评估框架的制定:药物政策视角报告2
Cost Eff Resour Alloc. 2021 Jul 15;19(1):42. doi: 10.1186/s12962-021-00296-2.
8
Proposal for capturing patient experience through extended value frameworks of health technologies.通过扩展健康技术的价值框架来获取患者体验的建议。
J Manag Care Spec Pharm. 2021 Jul;27(7):936-947. doi: 10.18553/jmcp.2021.27.7.936.
9
Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand.印度尼西亚和泰国医院在招标和采购决策中实施多标准决策分析(MCDA)的案例研究。
J Pharm Policy Pract. 2021 Jun 14;14(1):52. doi: 10.1186/s40545-021-00333-8.
10
Priority setting in the Brazilian emergency medical service: a multi-criteria decision analysis (MCDA).巴西急救医疗服务中的优先级设置:多准则决策分析(MCDA)。
BMC Med Inform Decis Mak. 2021 May 6;21(1):151. doi: 10.1186/s12911-021-01503-z.